www.epinex.com
Open in
urlscan Pro
34.149.87.45
Public Scan
Submitted URL: http://www.epinex.com/
Effective URL: https://www.epinex.com/
Submission: On October 11 via api from US — Scanned from DE
Effective URL: https://www.epinex.com/
Submission: On October 11 via api from US — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
Skip to Main Content * Home * Company * Company Overview * Management * Business Advisory Board * Scientific Advisory Board * Products * The Epinex G1A Test * The Epinex ACR Test * The Epinex SimplySure PT-INR Test * Technology * Technology Overview * The Epinex G1A Test * The Epinex ACR Test * The Epinex SimplySure PT-INR Test * Intellectual Property * Domains * Market * Market Overview * The Epinex G1A Test * The Epinex ACR Test * The Epinex SimplySure PT-INR Test * Investor Relations * Shareholder Website * Corporate Profile & Governance * Investor Documents * News/Publications * Newsroom * Corporate Information Series * Scientific Reviews * Contact * Blog * Jobs/Internships * More Use tab to navigate through the menu items. Know more A MONTHLY TEST FOR DIABETES The Epinex G1A Test: The Key to Better Diabetes Control * * This Product is under development and intended for information and evaluation purposes only. It is NOT APPROVED by the FDA GLYCATED ALBUMIN THE CHALLENGE OF DIABETES THE EPINEX G1A TEST THE EPINEX ACR TEST SIMPLY-SURE PT INR TEST EPINEX DIAGNOSTICS: DEVELOPING INNOVATIVE TESTS FOR UNDERSERVED MARKETS * * * * Epinex is founded on the principle of applying expert scientific knowledge and proprietary technology for the benefit of users and the healthcare system. We are dedicated to advancing the technology of rapid diagnostics in order to provide easy access to critical diagnostic information at low cost. Our goal is to enhance patients' quality of life with diagnostic tests at the office, point of care, and over the counter to reduce costs, alleviate patient anxiety, enable earlier therapeutic intervention, and improve patient outcome. EPINEX PLATFORM TECHNOLOGY Epinex product research has developed a proprietary platform for rapid tests that exploits existing technology of immunoassay strips and biosensors to create unique quantitative diagnostic tests. What is Glycated Albumin? DOWNLOAD AM I DIABETIC APP * Shareholder Conference Call on June 10,2021 @4PM PT (see email or call the office for details) * A new article in JAMA reports self-blood glucose monitoring for type 2 diabetes is not necessary. Is there an alternative? * Latest Interview with Huffington Post * Epinex's Research on GA and Inflammation gets published by Springer Nature. 2017 * Epinex's Scientific Advisory Board, Alan Carter Presents at ADA 2017 * Epinex Diagnostics, Inc. is going to participate in the Bio CEO & INVESTOR CONFERENCE on February 13-14, 2017 in New York City, NY. * Japanese Patent Application for ACR Published * Chinese Patent Publication- Rapid Test for Urine Albumin and Urea Creatinine * "Glycated albumin, HbA1c levels linked in impaired glucose tolerance" * Glycated Albumin: The Next A1c? performance * Frost & Sullivan Lauds Epinex Diagnostics' Monthly G1A Test as a Superior Alternative to the Existing Diabetes Management Paradigm * Empower patients to self-manage chronic conditions * Improve doctor-patient communication * Improve patient outcome * Reduce healthcare costs OUR TESTS HAVE THE POTENTIAL TO NEWS PATENTS MORE CORPORATE INFORMATION SERIES Understanding Diabetes Diabetes Prevention – Challenge and Opportunity Glycated Albumin and Diabetes Monitoring Research Update Towards a New Glycation Index MORE Company Product Technology Markets Investor Relations Company Overveiw G1A Test Overview Overview Shareholder Website Management ACR Test G1A Test G1A Test Corporate Profile & Governance Advisory Board SimplySure PT-INR Test ACR Test ACR Test SimplySure PT-INR Test SimplySure PT-INR Test Intellectual Property Publications Contact Corporate Information Series Scientific Reviews © 2016 by Epinex Diagnostics Inc Epinex-G1A-Glycated Albumin-Monthly Diabetes Test FOLLOW US: * * *